LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/People In The News/Eric Gilbert: Ascendx Spine’s New VP
People In The News

Eric Gilbert: Ascendx Spine’s New VP

March 29, 2012 2 min read Premium comments

Advertisement

Eric Gilbert: Ascendx Spine’s New VP
Eric Gilbert

Eric W. Gilbert, formerly of Stryker Corporation, is now Vice President of Sales & Marketing for U.S. operations at Ascendx Spine. Gilbert, who holds a bachelor’s degree in business administration Western Michigan University, was Director of Corporate Business Development at Stryker. At Ascendx Gilbert will be focusing much of his initial efforts on the Ascendx Acu-Cut VCF [vertebral compression fractures] Augmentation System.

During his tenure at Stryker, Gilbert held various marketing and business development roles and was responsible for creating and launching the entire Stryker Interventional Spine product platform. Following Stryker, Gilbert was Director of Marketing for the fracture business of Spine Wave, Inc. Most recently, he was Executive Vice President, Sales & Marketing, for Universal Medical, a regional distributor of spinal and orthopedic implants and pharmaceuticals and a worldwide distributor of bracing equipment.

“Eric will play a lead role in rolling out the U.S. launch of our initial FDA-cleared product, the Ascendx Acu-Cut VCF Augmentation System, ” said Julian M. Mackenzie, CEO of Ascendx Spine, in the March 23, 2012 news release.

The company has designed its Acu-Cut Vertebral Augmentation System to be an alternate solution for physicians who are currently treating VCF patients. Acu-Cut is a uni-pedicular vertebral augmentation system that creates a cavity for precise cement placement. While traditional technologies require passing next to both sides of the spinal cord to reach the entire vertebral body, the Acu-Cut Vertebral Augmentation System is designed to achieve this through single-sided access.

When asked what he thinks will be the most interesting part of his new position, Gilbert told OTW,

I have been fortunate to be part of this market since its inception and have observed the customer’s desire to inject cement while having the fracture of vertebral body reduced. I see Ascendx Spine looking to design future products that have the potential to achieve this customer desire. Based on published biomechanical data and the use of the technology that Ascendx Spine is creating, I am very interested to see if in the future we can significantly reduce the incidence of subsequent fractures.

As for what his first steps will be in rolling out the U.S. launch of the Ascendx Acu-Cut VCF Augmentation System, Gilbert commented to OTW, “Knowing that this will be the first of many products for Ascendx Spine to commercialize in the U.S. market, I am currently looking to find the best fit for distribution into the three specialties treating VCF, creating product awareness and re-engaging many of the relationships I have been fortunate establish in this market over the past 10+ years.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy